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While ischaemic stroke remains a leading cause of death and disability, there have been recent advancements in treatment
modalities including thrombolysis and decompressive hemicraniectomy. A retrospective review of patients treated in our NHS
teaching hospital, in Plymouth (UK), over a 2 year period identiﬁed 17 thrombolysed patients, of whom two had undergone
subsequent decompressive hemicraniectomy. These were non-dominant hemisphere strokes in young patients, aged 51 and
57. Initial NIHSS scores were 16 and 17, and they received thrombolysis at 2hrs 42min and 5hrs 10min post onset of
symptoms respectively. CT imaging demonstrated cerebral swelling with signiﬁcant midline shift in both cases, and decompressive
hemicraniectomy was undertaken at 29hrs 8min and 27hrs 30min post-thrombolysis. We found no signiﬁcant intra-operative
complications attributable to prior use of thrombolytics. Both patients have had acceptable psychological and physical outcomes,
with Barthel Index scores of 40 and 25, and MMSE scores of 29/30 and 27/30. We conclude that the use of thrombolytic therapy
does not contra-indicate subsequent decompressive hemicraniectomy in well selected patients with non-dominant hemisphere
strokes. More research in this ﬁeld is required to elucidate factors which would facilitate recognition of stroke patients who will
beneﬁt most from aggressive medical and neurosurgical intervention.
1.Introduction
The acute treatment for ischaemic stroke, a leading cause
of death and permanent disability in the Western world,
underwent profound changes after the randomised double-
blind NINDS study of intravenous thrombolysis in 1995
[1]. Despite its beneﬁts, thrombolysis has remained an
underused intervention perhaps due to its short window of
eﬃcacy, although this is being reconsidered [2], and delayed
presentations to hospital are being addressed with multiple
public health campaigns. Its beneﬁts are, however, clearly
documented. ECASS II [3], a multicentred European trial
of 800 patients, using Alteplase (0.9mg/kg) intravenously
(IV), combined with strict CT and blood pressure inclusion
criteria, supported the use of Alteplase within 3 hours of
symptomonset.Thepotentialbeneﬁtswerecounterbalanced
by a 2- to 5-times increase in symptomatic intracranial
haemorrhage. The NINDS study [1] suggested that intrac-
erebral haemorrhage occurred in 5.8% of patients receiving
tPA, which was associated with a 45% fatality rate.
In parallel with recent studies of thrombolysis, there
has been an increase in interest in decompressive hemi-
craniectomy for anterior circulation ischaemic strokes since
its initial description in 1935 [4] .L a r g ec e r e b r a li n f a r c t sa r e
oftenassociatedwithsigniﬁcantcerebraloedema,whichmay
be signiﬁcant enough to cause herniation and death. Hem-
icraniectomy was devised to counteract this postinfarction
complication. This is most commonly a phenomenon of the
second to ﬁfth days after ictus [5], and half of deaths within
the ﬁrst month of young patients with ischaemic stroke can
be attributed to space-occupying malignant infarction [6].
Again, this treatment is not without its controversies, the
most predominant of which being that while it prevents
death, it may promote life but with complete dependence.2 Cardiovascular Psychiatry and Neurology
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Recently, pooled data from three European multicentered,
randomised, controlled trials (DECIMAL, DESTINY, and
HAMLET) has suggested mortality and poor functional
outcome can be improved by undertaking decompressive
hemicraniectomy without increasing the numbers of com-
pletely dependent patients [7].
Combining these two interventions oﬀers further oppor-
tunities to improve patient outcomes, but also raises further
questions.Mostpredominantisthefearthatprecedentuseof
thrombolysis could predispose patients to excess risk of both
intraoperative andpostoperative haemorrhage.We soughtto
investigate this possibility in this retrospective analysis.
2. Methods
We examined clinical and surgical outcomes when decom-
pressive hemicraniectomy was undertaken following intra-
venous thrombolysis in the same patients, and speciﬁcally
when hemicraniectomy was undertaken for space-occupying
cerebral oedema rather than post-thrombolysis haemor-
rhage. We analysed data from a cohort of patients treated in
Derriford Hospital over a 30-month period from 13/05/2006
to 29/01/2009. Patients were identiﬁed by searching the
hospital clinical coding database, using procedure codes for
thrombolysis. The patients excluded either were thrombol-
ysed for other reasons (e.g., myocardial infarction) or did
not subsequently undergo hemicraniectomy. A total of 17
patients received intravenous thrombolysis between these
dates, and two of these patients subsequently underwent
decompressive hemicraniectomy. We undertook a detailed
case notes study with interest focused on intraoperative and
perioperative issues regarding the recent use of thrombolysis
and patients’ long-term outcome.
Case 1 (SK (Figure 1)). A 51-year-old right-handed female
presentedtotheemergencydepartmentat10:25on12/08/08,
with a sudden onset left hemiplegia, occurring at 09:18, and
involvingtheuppermotorneuroneoftheVIIthcranialnerve
and her upper and lower limbs, and a left-sided hemineglect.
On admission her GCS was 15. Her past medical history
included Hepatitis A in 1967. She had no medical allergies,
and, aside from the oral contraceptive pill, she was on no
medications. There was no contributory family history, and
she was a life-long nonsmoker.
AnoncontrastCTbrainscanat11:23demonstratedchar-
acteristic grey and white matter changes in the right middle
cerebral artery (MCA) territory and density within the right
MCA, indicating acute infarct. There was no evidence of
acute haemorrhage or hydrocephalus. Her admission blood
proﬁle was unremarkable (Hb 14.4, PLT 235, PT 12.8, APTT
23.2).
She was diagnosed with a right MCA ischaemic stroke,
and, following appropriate consent, recombinant tissue
plasminogen activator (rTPA), Alteplase was administered at
12:00. She was given a 5.4mg bolus over 2min, and then
an infusion of 48.6mg over the subsequent hour. A total
of 54mg rTPA was administered intravenously. Her blood
pressure remained stable throughout.
Her neurological status remained unchanged until
13/08/08 when her GCS dropped to 9 (E3V1M5), and a
CT brain scan (at 15:24) demonstrated an extensive right
anteriorcerebralartery(ACA)andMCAterritoryinfarction.
The associated mass eﬀect resulted in 10mm of midline shift
to the left. There was radiological evidence of right uncal
herniation. No intracranial haemorrhage was demonstrable.
After failed medical control of ICP, she underwent
an emergency decompressive hemicraniectomy at 18:15 on
13/08/08. A standard operative protocol was used: a trauma
ﬂap was fashioned and frontotemporoparietal craniotomy
was performed, and the dura was incised in a stellate pattern.
The dura was left open, and an artiﬁcial dural patch (Dura-
Guard, Synovis, St. Paul, USA) was laid over the defect. No
subgaleal drain was sited. Routine bipolar diathermy was
suﬃcient for haemostasis. This was an uncomplicated proce-
dure. Her postoperative haemoglobin was 11.7 (preoperative
was 14.4). No intraoperative blood component transfusions
were administered, though, one day later, she received a 2-
unit packed red cell transfusion.
Thereafter, she was managed on the intensive therapy
unit (ITU) for medical optimisation of her intracranial pres-
sure (ICP). Clexane 40mgs/c, Aspirin 75mg, and Clopido-
grel 75mg were commenced within a week. A routine post-
operative scan on 26/08/08 was satisfactory. The evolution of
radiological changes on CT scanning are shown in Figure 1.
Shewastransferredforphysicalandneurologicalrehabil-
itation three weeks after surgery. At her most recent outpa-
tient review (6 months after surgery), her MMSE was 29/30.
She was able to move from lying to sitting independently, to
transfer from bed to chair and chair to car with the assistance
of one, to stand with supervision of one, and to walk 20
metres with hand-rail assistance. She lives in a nursing
home, with no diﬃculties with swallowing or meeting her
nutritional needs, and she is continent. She had required
antidepressant medication during rehabilitation, though this
is no longer the case. She has a Barthel Index Score of 40.
Case 2 (DH (Figure 2)). A 57-year-old right-handed male
presented with sudden onset left hemiplegia at 13:30 on the
09/01/09 involving the upper motor neurone of the VIIth
cranial nerve, and his left upper and lower limbs, but with
a GCS of 15. His past medical history included right-sided
sciatica and a childhood hypospadias repair. He had no
medical allergies, nor used regular medications. He was a
nonsmoker with an unremarkable family history.
A noncontrast CT brain scan at 17:03 demonstrated
clear evidence of an acute, nonhaemorrhagic infarct in theCardiovascular Psychiatry and Neurology 3
right MCA territory, occupying greater than 50% of the
usual MCA territory. Thrombus was seen in the right MCA.
Routine investigations of blood parameters were unrema-
rkable (Hb 14.9 PLT 242 PT 14.0 APTT 28.4).
He was consented for oﬀ-licence thrombolysis with
Alteplase. This was commenced at 18:40 with a bolus of
6.3mg over 2 minutes, followed by a 56.7mg infusion over
the subsequent hour. Thus, a total of 63mg was prescribed
intravenously. Blood pressure was monitored throughout
the infusion, and there were no hypertensive episodes during
administration.
The infusion was stopped early, after 53mg total dose,
as the patient developed a generalised tonic-clonic seizure. A
repeat CT brain scan at 20:10 demonstrated evolving MCA
territory malignant infarction with no evidence of acute
haemorrhage, and the patient was subsequently intubated
and ventilated on ITU.
Evolution of a ﬁxed right mydriatic pupil was noted
on the 10/01/09, and a repeat CT brain scan at 16:43
demonstrated that the cerebral oedema associated with the
MCAinfarcthadsigniﬁcantlyprogressedwith12mmshiftin
midline structures to the left. A left-sided intraparenchymal
ICP bolt was inserted at 17:30, and ICP readings remained
at 18–20cm H20 despite optimal medical intervention.
On 10/01/09, a decision was made to proceed with deco-
mpressivehemicraniectomyduetorefractoryICPs.Asimilar
procedure was undertaken: the dura was opened, and an
artiﬁcial dural patch (Dura-Guard) was laid over the defect.
A subgaleal drain was sited for 48 hours. Bipolar diathermy
was suﬃcient for haemostasis. There was a 220mL blood
loss intraoperatively. Postoperative Hb was 11.2 (14.3 preo-
peratively), and no intraoperative or postoperative blood
component transfusions were required.
A routine postoperative scan demonstrated a maturing
infarctinvolvingthewholeoftherightMCAterritory,butno
intracranialhaemorrhage. Theshift of themidline structures
had resolved, and the basal cisterns were patent. He was
later discharged to intensive physical and neurological
rehabilitation. Serial CT scan ﬁndings are shown in Figure 2.
On review nine months after stroke, his level of function
allowed transfer from bed to chair with the assistance of one,
and standing with two for short periods. He is independently
mobile in a wheelchair. He is able to write independently,
and his cognition is intact with only mild memory deﬁcit
(MMSE 27/30). There is no deﬁcit in swallow safety, and
no requirement for nutritional support. The cranial vault
defect has been repaired with a titanium cranioplasty. He
does, however, lack some insight into his physical condition
and potential, and has required antidepressant medication.
Due to impaired mobility, he has suﬀered with double
incontinence. His Barthel Index Score is 25.
3. Discussion
Tissue plasminogen activator (t-PA) is an exogenous stim-
ulator of the ﬁbrinolytic system which degrades ﬁbrin clots
through activation of plasminogen to plasmin [8]. Plasmin
not only lyses the ﬁbrin component of a blood clot but also
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contributes to tissue remodelling by degrading extracellular
matrix proteins, either directly or via the activation of matrix
metalloproteinases [9].
In nonsurgically managed patients, serious complica-
tions of t-PA include systemic bleeding and anaphylaxis,
but the most worrisome adverse reaction is intracerebral
haemorrhage (ICH). Studies demonstrate symptomatic ICH
occurs within 36 hours of treatment in 6.4% of patients
treated with t-PA compared with 0.6% of patients treated
with placebo. Despite this increased haemorrhage rate,
mortality was similar in both groups with a trend toward
increased mortality in the placebo group (21%) compared
with the treatment group (17%) [1].
Moreover, there is a further concern that if neurosurgery
is undertaken after intravenous thrombolysis, there may
be an increased risk of perioperative haemorrhage, with
signiﬁcant risk of mortality. However, t-PA is rapidly cleared
from the plasma at 550–680mL/min, giving an initial dis-
tribution phase half-life of under 5 minutes, and a terminal
elimination phase of approximately 40 minutes. Thus, 50%
of t-PA is cleared from the plasma within 5 minutes after
discontinuation of an IV infusion, and approximately 80%
is cleared within 10 minutes.
Malignantinfarctionandresultantspace-occupyingcere-
bral oedema is most common between the second and ﬁfth
days postictus [5], and, given the short serum half-life of t-
PA, it is likely that any excess haemorrhage risk has returned
to baseline at the time when neurosurgical intervention is
being considered. However, there is little experimental or
anecdotal evidence to conﬁrm this hypothesis at present, and
the evidence will need to be examined in greater detail before
deﬁnitive conclusions on the safety of major neurosurgical
intervention following thrombolysis can be reached.
This study has identiﬁed two cases in which both
thrombolysis and decompressive hemicraniectomy have
been undertaken in the same patients. In both cases, the
patients rapidly underwent thrombolysis, and subsequently
underwent emergency neurosurgery, and both patients sur-
vived with the avoidance of a vegetative state (Table 1).
Furthermore, neither patient suﬀered any haemorrhagic
complication of undergoing both interventions.
A recently published study [10] of mortality following
stroke reported 17 patients who underwent hemicraniec-
tomy following initial thrombolysis. It was demonstrated
that thrombolysis prior to hemicraniectomy had no eﬀect on
inpatienthospitalmortality(oddsratio1.21,95%conﬁdence
interval 0.43, 3.39). In support of this ﬁnding, our case
reports may point the way for further studies into the4 Cardiovascular Psychiatry and Neurology
Table 1
Patient 1 Patient 2
Age 51 57
Time from onset of symptoms to
arrival to hospital 1hr 7min 2hrs 8min
NIHSS scores on admission 16 17
Time from onset of symptoms to
thrombolysis 2hrs 42min 5hrs 10min
Time from onset of symptoms to
operation 32hrs 57min 32hrs 40min
Time between thrombolysis and
operation 29hrs 8min 27hrs 30min
Barthel index scores 40 25
Mini-mental state examination 29/30 27/30
role of neurosurgical intervention following intravenous
thrombolysis. While it is impossible to make any deﬁnitive
conclusions from a case series of two patients, we found
no evidence that hemicraniectomy is associated with excess
haemorrhage risk in patients receiving prior thrombolysis.
More research into these treatments is needed to further
elucidate the potential for both modalities to be used in
appropriate patients.
Despite these successful cases, our ﬁndings clearly have
caveats.Thesearebothyoungpatients,andselectionforsuch
aggressive interventions is appropriately biased in favour of
the younger patient in whom the outcomes after stroke are
demonstrably better. Both were nondominant hemisphere
stokes, and clearly remained signiﬁcantly disabled. There-
fore, it would be unwise to extrapolate any ﬁndings to
dominant hemisphere strokes.
4. Conclusions
Intracerebral haemorrhage is a potentially fatal complication
of intravenous thrombolysis. However, there is very little
evidence to support or refute the hypothesis that prior
thrombolysis results in excess haemorrhage risk for patients
whosuﬀerspace-occupyingcerebraloedemaandareselected
for subsequent decompressive hemicraniectomy. Decom-
pressive hemicraniectomy following thrombolysis represents
an aggressive treatment paradigm, and the decision to
proceed with such intervention requires a multidisciplinary
team approach and a frank and open discussion with
patients and/or their relatives. Whilst decompressive hem-
icraniectomy may preserve both life and function in well-
selectedpatients,thepotentialrisksofsurgery,includinglife-
threatening haemorrhage, must be discussed with patients
and/or relatives in order to obtain a fully informed consent.
This case series supports the hypothesis that decompressive
hemicraniectomy following intravenous thrombolysis is not
associated with excess haemorrhage risk. However, deﬁnitive
guidelines must be based on larger prospective clinical
studies.
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